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Abstract
Background & Aims—Gastrointestinal (GI), liver, and pancreatic diseases are a source of 
substantial morbidity, mortality, and cost in the United States (US). Quantification and statistical 
analyses of the burden of these diseases are important for researchers, clinicians, policy makers, 
and public health professionals. We gathered data from national databases to estimate the burden 
and cost of GI and liver disease in the US.
Methods—We collected statistics on healthcare utilization in the ambulatory and inpatient 
setting along with data on cancers and mortality from 2007 through 2012. We included trends in 
utilization and charges. The most recent data were obtained from the Centers for Disease Control 
and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer 
Institute.
Results—There were 7 million diagnoses of gastroesophageal reflux and almost 4 million 
diagnoses of hemorrhoids in the ambulatory setting in a year. Functional and motility disorders 
resulted in nearly 1 million emergency department visits in 2012; most of these visits were for 
constipation. GI hemorrhage was the most common diagnosis leading to hospitalization, with 
more than 500,000 discharges in 2012 at a cost of nearly $5 billion dollars. Hospitalizations and 
associated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic 
liver disease have increased over the last 20 years. In 2011, there were more than 1 million people 
in the US living with colorectal cancer. The leading GI cause of death was colorectal cancer, 
followed by pancreatic and hepatobiliary neoplasms.
Conclusions—GI and liver diseases are a source of substantial burden and cost in the US.
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Gastrointestinal (GI) and liver diseases are highly prevalent, costly and lead to substantial 
health care utilization in the United States. Many of these diseases also affect patients’ 
quality of life and productivity.1 Given this burden of disease, the National Institutes of 
Health plans to devote an estimated $1.6 billion dollars to GI research and another $619 
million dollars to liver disease research in 2015.2
Statistics quantifying the burden of GI and liver diseases are valuable in public health 
research, decision-making, priority-setting, and resource allocation. Reports describing the 
epidemiology of GI and liver diseases have been published and are commonly referenced for 
these reasons.1,3–8 We took advantage of recently available statistics to provide an update to 
our previous report.1
The objective of this work was to create a complete and accurate report detailing the current 
state of GI and liver morbidity, mortality, and cost in adults in the United States. We 
gathered data from several complementary national databases to achieve this objective.
Methods
We compiled the most recently available statistics from several publicly available databases. 
We utilized material available in the public domain or limited data sets with no direct patient 
identifiers. The methods used to collect the data from the source databases are detailed 
below.
Symptoms and Diagnoses across Ambulatory Settings
We tabulated the leading GI symptoms and diagnoses in the United States from the National 
Ambulatory Medical Care Survey (NAMCS) for office-based outpatient visits and the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) for emergency department 
and hospital-based outpatient visits for 2010. NAMCS and NHAMCS are annual national 
surveys sponsored by the US Centers for Disease Control and Prevention (CDC) to provide 
reliable information about the provision and use of ambulatory medical care services in the 
United States (http://www.cdc.gov/nchs/ahcd.htm). The NAMCS collects data on visits to 
non-federal employed office-based physicians or non-physician clinicians who are primarily 
engaged in direct patient care. The NHAMCS collects data on visits to emergency 
department and hospital-based outpatient visits exclusive of Federal, military, and Veterans 
Administration hospitals.
To perform our analyses, we downloaded the public use data files from the CDC website. 
Both NAMCS and NHAMCS collect data on patient-reported symptoms. We used the 
patients’ most important complaint (variable RFV1) for the visit in our analyses. We 
combined related symptoms (Appendix 1) and we totaled and ranked data from office visits, 
emergency department and hospital outpatient departments. Physician and non-physician 
clinician diagnoses were categorized into relevant disease categories based on clinical 
expertise using International Classification of Diseases, 9th Revision, Clinical Modification 
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(ICD-9-CM). We used the primary diagnosis code only. After combining the related 
diagnoses into clinically meaningful disease groups, we created a rank order list. NAMCS 
and NHAMCS are based on probability samples. Therefore, sampling weights were applied 
to all analyses in order to generate national estimates. These analyses were conducted using 
SAS v9.3 (Cary, NC).
Emergency Department Visits
We compiled the most common and selected other emergency department (ED) GI and liver 
principal visit discharge diagnoses from the 2012 Nationwide Emergency Department 
Sample (NEDS) (http://hcup.ahrq.gov/hcupnet.jsp). The NEDS was developed by the 
Agency for Healthcare Research and Quality and is part of the Healthcare Cost and 
Utilization Project (HCUP). The NEDS includes discharge data for emergency department 
visits from 950 hospitals located in 30 States and is the largest all-payer database in the 
United States.
To perform our analyses, we utilized the ‘National Statistics on All ED Visits’ link on the 
HCUP website. We first created a list of the most common GI diagnoses in 2012. To do this, 
we queried the NEDS to generate a list of the top 100 principal diagnoses and then limited 
our list to GI and hepatology diagnoses only. We combined related diagnosis codes. We 
then performed a query for each individual ICD-9-CM code (or group of codes) to 
determine the total number of visits, number of visits per 100,000 people, the total number 
of patients admitted to the same hospital from the emergency department (ED) with that 
diagnosis and proportion of deaths either in the hospital or the ED. We also performed a 
temporal analysis to determine admission trends between the year 2006 (first year available 
in NEDS) and 2012. Finally, we created a list of select emergency department GI and liver 
principal discharge diagnoses that were not among the top 100 discharge diagnoses with 
methods similar to those detailed above.
Hospitalizations
The most common inpatient GI and hepatology discharge diagnoses were compiled from the 
Nationwide Inpatient Sample (NIS), one of the databases in the Healthcare Cost and 
Utilization Project (HCUP) (http://hcup.ahrq.gov/hcupnet.jsp). The 2012 NIS contains a 20 
percent sample of discharges from 4,378 community hospitals participating in HCUP across 
44 states. The sampling frame for the 2012 NIS comprises approximately 95 percent of the 
U.S. population, and includes more than 94 percent of discharges from U.S. community 
hospitals. The NIS is the only national hospital database containing hospital charges for all 
patients, regardless of payer, including persons covered by Medicare, Medicaid, private 
insurance, and the uninsured.
To perform our analyses, we utilized the ‘National Statistics on All Stays’ link on the HCUP 
website. We queried the 2012 database for the top principal discharge diagnoses for all 
patients in all hospitals. From the top 100 diagnoses, we identified the GI and hepatology 
diagnoses and then rank-ordered then after combining related diagnosis codes. We then 
performed a separate query for each individual ICD-9-CM code (or group of codes) to 
acquire data on mean and median length of stay (LOS), median charges and costs, aggregate 
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charges and aggregate costs, and number of inpatient deaths associated with each diagnosis 
or diagnosis group. We calculated the change in the number of admissions for the top 
principal GI diagnoses between the year 2003 and 2012 to identify relevant trends over the 
10 year period. The total length of stay (LOS) was estimated by the product of the mean 
LOS and the number of discharges for each diagnosis. Total charges were converted to costs 
by HCUP using cost-to-charge ratios based on hospital accounting reports from the Centers 
for Medicare and Medicaid Services (CMS). Cost data are presented rather than charges, as 
costs tend to reflect actual expenditures, while charges represent what the hospital billed for 
the case. In diagnosis categories represented by multiple ICD-9-CM codes, median LOS and 
median costs are presented for most common ICD-9-CM code in these categories. Rate of 
visits, admissions and deaths represent the sum from all codes. Total hospital days per year 
for all persons with each diagnosis were estimated from the product of the number of 
discharges and mean LOS.
Finally, we reviewed the 10-year trend data and based on these numbers chose to perform 
temporal analyses for the number of admissions and associated costs for Clostridium 
difficile, inflammatory bowel disease, and liver disease between the year 1993 and 2012. For 
charge trends, we graphed the actual charges per calendar year, as well as inflation-adjusted 
charges (2012 dollars) using the Consumer Price Index published by the US Bureau of 
Labor Statistics (www.bls.gov). Linear regression was used to determine statistical 
significance of trends over time.
Cancer
We collected GI and liver cancer statistics from the Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute (www.seer.cancer.gov).9 The 
SEER program collects and publishes cancer statistics from a collection of population-based 
cancer registries and represents approximately 28 percent of the United States population. 
We gathered the most recent version of the SEER estimates available from the SEER Cancer 
Statistics Review.9 Incidence rates were age adjusted and based on 2007–2011 cases. New 
cases were estimated for 2014. Prevalence was estimated for 2011. Lifetime risk was based 
on 2009–2011 data.
Mortality
We generated a list of the most common GI and liver causes of death using data from the 
Centers for Disease Control Wide-ranging Online Data for Epidemiologic Research (CDC 
WONDER) (http://wonder.cdc.gov). CDC WONDER is a publically available database 
provided by the Centers for Disease Controls. The CDC maintains county-level, national 
mortality of children and adults collected and reported by state registries. Underlying and 
contributing causes of death are derived from death certificates and are classified by 
International Classification of Diseases, 10th edition (ICD-10). The underlying cause of 
death is defined as the disease that initiated the sequence of morbid events leading directly 
to death. Contributing cause of death statistics include all deaths with the disease of interest 
as either the underlying cause or any of 20 additional diseases leading to death.
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To perform our analyses, we downloaded the 2012 public use data files for underlying cause 
of death and multiple cause of death from the CDC website. Using ICD-10 codes, the 20 
most common GI and liver causes of death were ranked. Diagnoses were combined to create 
clinically meaningful categories. The crude rate per 100,000 deaths was calculated by 
dividing the number of deaths listed as an underlying cause by the total U.S. population in 
the United States in 2012 (314,112,078 from the U.S. Census Bureau)10 then multiplying by 
100,000. Results include children and adults. These analyses were conducted using Stata MP 
v13.0 (College Station, Texas).
Results
Symptoms and Diagnoses across Ambulatory Settings
The leading GI symptoms prompting a visit in 2010 are shown in Table 1. Abdominal pain 
was responsible for more than 27 million total visits, followed by diarrhea, vomiting, 
nausea, and bleeding. Constipation and anorectal symptoms accounted for 3.0 and 2.6 
million visits, respectively.
Abdominal pain is also the most frequent diagnosis (Table 2) with nearly 17 million annual 
visits. There were more than 7 million visits with GERD and reflux esophagitis. 
Hemorrhoids accounted for nearly 4 million visits.
Emergency department visits
The most common GI discharge diagnoses from the emergency department in the U.S. in 
2012 as captured by the NEDS are detailed in Table 3. Abdominal pain was the most 
frequent visit diagnosis with an estimated 5.7 million visits. This diagnosis was rarely 
associated with admission to the hospital or death. GI hemorrhage was also a common 
discharge diagnosis almost 800,000 visits. More than half of these visits resulted in a 
hospital admission. Mortality from GI hemorrhage is substantial (10,393 deaths, 1.3% 
visits). Constipation was also common with nearly 800,000 visits and the number of ED 
visits for constipation has increased 60% since 2006.
Select GI and liver discharge diagnoses are detailed in Table 3. Functional and motility 
disorders had close to a million visits and increased by 39% since 2006. The majority of 
these visits were for constipation, as per Table 3. ED visits for liver disease and 
inflammatory bowel disease have both increased since 2006, and both disorders result in 
hospital admission in a majority of cases.
Hospitalizations
The most common GI and liver discharge diagnoses from hospital admissions are detailed in 
Table 4. GI hemorrhage was the most frequent discharge diagnosis with more than 500,000 
discharges in 2012 at a cost of nearly $5 billion dollars. Hospitalizations for Clostridium 
difficile infection and associated charges continue to increase as illustrated in Figure 1A and 
Figure 1B. Regardless of inflation, the increases in spending are statistically significant 
(p<0.0001). There are higher aggregate costs for chronic GI conditions, such as 
inflammatory bowel disease, motility disorders, and chronic liver disease, despite fewer 
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number of total hospital days. Hospitalizations and charges for inflammatory bowel disease 
and chronic liver disease in particular have increased over the last twenty years as seen in 
Figures 1C–F. These increases in spending are also statistically significant, regardless of 
inflation (p<0.0001). These charges are also detailed in table format in Appendix 2. Chronic 
liver disease had the highest inpatient mortality (5.8%, with roughly 14,000 annual hospital 
deaths).
Some GI diagnoses were not among the “top 100” diagnoses overall, but do contribute to the 
burden of GI diseases. For example, chronic pancreatitis, with only 14,195 discharges, is 
very expensive (aggregate cost ~$150 million). Eating disorders, though an uncommon 
reason for hospitalization (n=5,865) are associated with long hospital stays (mean length of 
stay 12 days), high median charges ($51,847) and aggregate costs ($90,356,190).
Cancer
GI and liver cancer incidence, prevalence, and survival are detailed in Table 5. Using SEER 
data, the National Cancer Institute estimated that in 2011 there were more than a million 
people in the United States living with a diagnosis of colorectal cancer. They also estimated 
136,830 new cases of colorectal cancer each year with a 65% 5-year survival. The estimated 
lifetime risk of developing colorectal cancer in the United States is 4.7%. Pancreatic, gastric 
and esophageal cancers remain common and highly lethal GI malignancies, all of which are 
associated with <30% 5-year survival.
Mortality
The leading causes of death from GI and liver disease are presented in Table 6. The top 
three causes of death from GI and liver disease remain colorectal cancer followed by 
pancreatic, liver and intrahepatic bile duct cancers. All-cause cirrhosis contributed to 34,251 
deaths in the U.S.. Clostridium difficile continues to be a source of substantial significant 
mortality, accounting for 7,739 deaths in the U.S. in 2012.
Discussion
We have compiled the most recently available statistics from several complementary 
national databases to create a complete and accurate report detailing the current state of GI 
and liver morbidity, mortality, and cost in adults in the United States. GI and liver diseases 
account for substantial utilization of health care resources and cost in the United States. This 
report demonstrates several trends in the data worthy of highlighting.
The U.S population is growing older.11 This demographic is driven by the cohort of 
Americans born during the post-World War II baby boom (1945–1965). In 2011, the first 
baby boomers turned 65. This change in demographics is manifest in changes in liver 
disease in the U.S. Baby boomers are five times more likely to have chronic hepatitis C 
compared with adults born in other years.12 An estimated 2.7 million Americans have 
chronic HCV infection and most of those infected (75%) were born between 1945–
1965.12–14 We found a 176% increase in hepatitis C related emergency department visits 
between 2006 and 2012 and a 225% increase in hepatitis C admissions between 2003 and 
2012. In-hospital mortality was nearly 6%. Moreover, rates of new liver cancers are rising 
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and many of these cancers are attributable to chronic hepatitis C infection.15, 16 The 
incidence of end stage liver disease from chronic hepatitis C infection is predicted to 
increase until the year 2030.17
Other GI diagnoses associated with age are also increasing. There are an increasing number 
of anorectal symptoms reported by patients and physicians in the ambulatory setting 
commonly diagnose hemorrhoids. Between 2006 and 2012, there has been an increase in the 
number of patients seen for constipation and lower GI bleeding in the emergency 
department. Hospital admissions for acute diverticulitis and C. difficile are increasing. By 
2030, an estimated one in five Americans will be 65 or older. Even if the epidemiology of 
these conditions remains stable on an age-adjusted basis, we can expect increased numbers 
of cases and therefore increased utilization of health care and costs for these diseases.
The incidence of colorectal cancer and death rate from colorectal cancer in the United States 
continues to decrease and is in part attributable to screening and removal of adenomatous 
polyps.18–21 While this trend is encouraging, a substantial number of Americans are still 
diagnosed with and die from colorectal cancer every year. In 2014, an estimated 136,830 
people were diagnosed with colorectal cancer. In 2012, 51,139 people died from colorectal 
cancer. Despite the effectiveness of screening, in 2010 only 58% of adults aged 50 to 75 
years had received colorectal cancer screening based on U.S. Preventative Services Task 
Force guidelines.22 A new initiative from the National Colorectal Cancer Roundtable aims 
to increase colorectal screening in the United States to 80% by 2018, which would have the 
predicted benefit of preventing 280,000 cases of colorectal cancer and 200,000 deaths within 
20 years.23, 24
Hospitalizations account for a large portion of the economic burden of IBD. Over the last 
twenty years in the United States, despite advances in therapy, hospital admissions and 
associated charges for inflammatory bowel diseases have increased. This is congruent with 
earlier trends using the National Hospital Discharge Survey.7, 25, 26 Emergency department 
visits are also rising.
This report has important strengths. We have gathered data from several complementary 
national databases each designed specifically to assess utilization. Since our last report1 we 
have obtained data from the NHAMCS. Adding NHAMCS provides a more comprehensive 
picture of GI symptoms and diagnoses in the ambulatory setting with more than a third of 
visits occurring in hospital-based clinics and emergency departments. We have also added 
statistics from the NEDS and for the first time present data for emergency department visits 
from two sources with different methods to assess visits. Despite differences in 
methodology, the estimates generated from these two sources appear to be similar, 
increasing our confidence in their accuracy.
There are important limitations imposed with the use of administrative data and ICD codes. 
The fidelity of coding data to clinical information is imperfect. Some trends may reflect 
coding changes occurring during the observed time period (e.g. codes for ascites changed in 
2007). For most of our sources, data are coded by visit, and not by person, so a single patient 
could be represented by multiple visits or discharges. The methodology used in our data 
Peery et al. Page 7













sources can change over time. For instance, the NIS utilized a new sampling strategy for the 
2012 data. With this change, the estimated overall trends in discharge counts declined by 
about 4.3 percent, overall trends in average length-of-stay declined by about 1.5 percent, 
overall trends in total charges declined by about 0.5 percent, and overall trends in hospital 
mortality declined by about 2.0 percent. Costs are estimates calculated from charges based 
on Medicare cost-to-charge ratio. Our estimates do not include federal health care delivery 
sites. The National Vital Statistics System accounts for all deaths in the US but depends on 
the accuracy of the death certificates and therefore may underestimate mortality.27, 28
More than 16 million uninsured Americans have gained health insurance coverage since the 
Affordable Care Act’s provisions took effect. This sweeping legislation can be expected to 
change the landscape of care for GI illnesses. As health care access expands, and the 
financing of these services changes, researchers, clinicians, policy makers, and public health 
professionals now more than ever need a clear understanding of which conditions affect 
large portions of the populations and the costs inherent in the care of them. GI and liver 
diseases continue to account for substantial burden and cost in the United States.
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Appendix 1
Symptom Groupings from NAMCS/NHAMCS
RFV1 LABEL COUNT PERCENT
15451 ‘Abdominal pain, cramps, spasms, 
NOS’
9435447 22.1691855 Abdominal pain 15028011
15453 ‘Upper abdominal pain, cramps, 
spasms’
1136576 2.6704579
15452 ‘Lower abdominal pain, cramps, 
spasms,’
1010634 2.3745491





15950 ‘Diarrhea’ 4454522 10.466184 Diarrhea 4454522
15300 ‘Vomiting’ 2681315 6.2999209 Vomiting 2681315
15900 ‘Constipation’ 2472469 5.8092239 Constipation 2472469
15250 ‘Nausea’ 2343409 5.5059892 Nausea 2343409
16052 ‘Anal-rectal bleeding’ 1664572 3.9110183 Bleeding 2691658
15801 ‘Blood in stool (melena)’ 753950 1.7714537
15800 ‘Gastrointestinal bleeding’ 232363 0.5459517
15802 ‘Vomiting blood (hematemesis)’ 40773
2691658
16051 ‘Anal-rectal pain’ 1445408 3.3960784 Anorectal symptoms 2446210
16054 ‘Anal-rectal itching’ 335186 0.7875409
16053 ‘Anal-rectal swelling or mass’ 179550 0.4218642
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RFV1 LABEL COUNT PERCENT
16050 ‘Symptoms referable to anus-rectum’ 447253 1.0508495
16004 ‘Incontinence of stool’ 38813
2446210
0.0911936
15350 ‘Heartburn and indigestion 
(dyspepsia)’
1355288 3.1843357 Heartburn and indigestion 1355288
16150 Other and unspecified symptoms 
referable to the digestive systemic
1324906 3.1129513 Other GI symptoms, 
unspecified
1324906
15702 ‘Decreased appetite’ 837473 1.9676963 Decreased appetite 837473
15200 ‘Difficulty in swallowing 
(dysphagia)’
808250 1.899035 Dysphagia 808250
16000 Other symptoms or changes in bowel 
function
722827 1.6983282 Other changes in bowel 
function
1307775
16003 Changes in size, color, shape, or odor 584948
1307775
1.3743727
15850 ‘Flatulence’ 582303 1.3681581 Flatulence 582303
16100 Symptoms of liver, gallbladder, and 
biliary tract
188353 0.4425474 Symptoms related to the 





15651 ‘Abdominal distention, fullness, 
NOS’
291507 0.6849143 Abdominal distention 373732
15653 ‘Abdominal swelling, NOS’ 70454 0.1655362
15650 ‘Change in abdominal size’ 11771
373732
0.0276567
15050 ‘Symptoms referable to lips’ 566403 1.3308
15001 ‘Toothache’ 504037 1.1842671
15652 ‘Abdominal mass or tumor’ 400400 0.9407654
15100 ‘Symptoms referable to mouth’ 336032 0.7895287
15104 ‘Mouth ulcer, sore’ 321258 0.7548162
15150 ‘Symptoms referable to tongue’ 296148 0.6958186
15053 ‘Cold sore’ 225644 0.530165
15051 ‘Cracked, bleeding, dry lips’ 116390 0.2734657
15103 ‘Mouth dryness’ 114517 0.269065
15701 ‘Excessive appetite’ 98399 0.2311947
15151 ‘Tongue pain’ 93304 0.2192237
15750 ‘Difficulty eating’ 90538 0.2127248
15011 ‘Symptoms of the jaw, swelling’ 78977 0.1855615
15400 ‘Gastrointestinal infection’ 77764 0.1827115
15101 ‘Mouth pain, burning, soreness’ 46531 0.1093276
15802 ‘Vomiting blood (hematemesis)’ 40773 0.0957988
15012 ‘Symptoms of the jaw, lump or mass’ 35988 0.0845561
15000 ‘Symptoms of teeth and gums’ 20218 0.0475035
15102 ‘Mouth bleeding’ 20158 0.0473625
Appendix 2
Inflation-adjusted charges for GI hospitalizations
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Annual charges for C. diff-related hospitalizations, 1993 through 2012, National Inpatient 
Sample
Year Mean charges Actual aggregate charges Inflation - adjusted charges (2012 dollars)
1993 $11,548 $273,595,216 $434,711,557
1994 $11,309 $288,051,539 $446,254,420
1995 $11,719 $286,588,145 $431,751,434
1996 $12,011 $277,021,704 $405,369,797
1997 $13,119 $317,230,539 $453,795,815
1998 $13,301 $334,599,956 $471,301,486
1999 $14,316 $417,783,828 $575,754,263
2000 $15,810 $502,473,420 $669,947,052
2001 $18,372 $652,867,392 $846,861,220
2002 $20,646 $931,650,750 $1,189,001,792
2003 $24,040 $1,139,399,840 $1,421,735,689
2004 $24,535 $1,431,224,690 $1,739,547,917
2005 $26,809 $1,973,437,299 $2,319,966,018
2006 $27,789 $2,405,860,464 $2,739,936,148
2007 $31,499 $3,154,089,367 $3,492,587,098
2008 $33,331 $3,620,479,882 $3,860,793,663
2009 $33,779 $3,560,948,401 $3,810,868,928
2010 $34,174 $3,663,179,408 $3,857,026,956
2011 $35,334 $4,194,039,798 $4,280,833,352
2012 $35,214 $4,201,558,410 $4,201,558,410
Annual charges for IBD-related hospitalizations (combined UC and Crohn’s), 1993 through 
2012, National Inpatient Sample
Year Mean charges Actual aggregate charges Inflation-adjusted charges (2012 dollars)
1993 $12,805 $751,423,010 $1,193,925,360
1994 $13,521 $806,879,196 $1,250,031,188
1995 $13,448 $802,805,256 $1,209,444,029
1996 $13,659 $865,680,102 $1,266,761,997
1997 $14,090 $920,401,070 $1,316,626,562
1998 $14,888 $974,315,384 $1,372,374,026
1999 $14,796 $1,053,874,692 $1,452,360,781
2000 $16,760 $1,194,971,240 $1,593,253,350
2001 $18,288 $1,408,761,216 $1,827,362,275
2002 $20,318 $1,604,309,280 $2,047,469,621
2003 $22,545 $1,907,442,270 $2,380,094,024
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Year Mean charges Actual aggregate charges Inflation-adjusted charges (2012 dollars)
2004 $23,690 $2,110,542,100 $2,565,208,062
2005 $25,355 $2,229,744,055 $2,621,279,347
2006 $25,981 $2,236,444,480 $2,546,995,208
2007 $28,299 $2,443,194,165 $2,705,398,429
2008 $32,631 $3,257,356,944 $3,473,567,996
2009 $32,872 $3,181,878,112 $3,405,194,084
2010 $34,277 $3,331,313,076 $3,507,598,974
2011 $35,679 $3,566,936,667 $3,640,752,636
2012 $37,049 $3,673,037,860 $3,673,037,860
Annual charges for liver disease-related hospitalizations, 1993 through 2012, National 
Inpatient Sample
Year Mean charges Actual aggregate charges Inflation-adjusted charges (2012 dollars)
1993 $16,177 $2,401,632,255 $3,815,919,418
1994 $18,094 $2,756,797,142 $4,270,877,753
1995 $17,304 $2,633,399,391 $3,967,274,933
1996 $17,722 $2,799,163,282 $4,096,055,415
1997 $18,202 $2,893,893,178 $4,139,691,653
1998 $17,673 $2,920,518,969 $4,113,703,265
1999 $23,113 $3,896,558,485 $5,369,906,655
2000 $21,669 $3,839,816,809 $5,119,621,954
2001 $22,847 $4,115,772,745 $5,338,738,574
2002 $25,504 $4,752,736,726 $6,065,591,083
2003 $31,002 $6,205,607,440 $7,743,316,492
2004 $29,434 $6,006,104,668 $7,299,976,682
2005 $33,114 $6,680,995,303 $7,854,154,816
2006 $32,355 $6,684,530,895 $7,612,739,019
2007 $37,094 $7,698,349,247 $8,524,538,188
2008 $43,984 $9,770,589,440 $10,419,124,266
2009 $45,558 $10,120,566,475 $10,830,865,255
2010 $46,466 $10,780,950,651 $11,351,455,292
2011 $48,599 $11,388,653,380 $11,624,335,861
2012 $49,611 $12,063,851,846 $12,063,851,846
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